Pancreatic Cancer Organoids: An Emerging Platform for Precision Medicine?
Open Access
- 14 March 2023
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 890
Abstract
Despite recent therapeutic advances, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive malignancies, with remarkable resistance to treatment, poor prognosis, and poor clinical outcome. More efficient therapeutic approaches are urgently needed to improve patients’ survival. Recently, the development of organoid culture systems has gained substantial attention as an emerging preclinical research model. PDAC organoids have been developed to study pancreatic cancer biology, progression, and treatment response, filling the translational gap between in vitro and in vivo models. Here, we review the rapidly evolving field of PDAC organoids and their potential as powerful preclinical tools that could pave the way towards precision medicine for pancreatic cancer.Keywords
This publication has 69 references indexed in Scilit:
- Unlimited in vitro expansion of adult bi‐potent pancreas progenitors through the Lgr5/R‐spondin axisThe EMBO Journal, 2013
- Application of Concave Microwells to Pancreatic Tumor Spheroids Enabling Anticancer Drug Evaluation in a Clinically Relevant Drug Resistance ModelPLOS ONE, 2013
- Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)Annals of Oncology, 2011
- Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell nicheNature Medicine, 2009
- Hydrogels as extracellular matrix mimics for 3D cell cultureBiotechnology and Bioengineering, 2009
- Chemotherapy Sensitivity and Resistance Assays: A Systematic ReviewJournal of Clinical Oncology, 2004
- Multicellular spheroids: a three‐dimensionalin vitroculture system to study tumour biologyInternational Journal of Experimental Pathology, 1998
- Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancerAnti-Cancer Drugs, 1998
- Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivityAnti-Cancer Drugs, 1996
- Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testingEuropean Journal of Cancer and Clinical Oncology, 1991